Ticaros Co., Ltd. is a South Korean company located in Seongdong-gu. The firm develops next-generation immune and anticancer drugs. It was founded by Jae Won Lee, Kyungho Choi and Eun Young Choi. Jae Won Lee is the current CEO of the firm.

Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success. For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

The Istituto Superiore di Sanità (Italian National Institute of Health), also ISS, is an Italian public institution that, as the leading technical-scientific body of the Italian National Health Service (Servizio Sanitario Nazionale), performs research, trials, control, counseling, documentation and training for public health. The Institute is under the supervision of the Ministero della Salute (Ministry of Health).

ounded in 2014, Wuhan Bio-Raid Biotechnology Co., Ltd. is a high-tech enterprise focusing on CAR-T cell immunotherapy. Bio-Raid has developed a number of patented technologies, and established a broad pipeline of CAR-T product candidates covering blood and solid tumors and HIV areas of significant unmet medical need.

Part of SOL SpA, Diatheva SRL is a company headquartered in Italy. The firm manufactures diagnostic solutions.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Leiden University Medical Center (Dutch: Leids Universitair Medisch Centrum) or LUMC is the university hospital affiliated with Leiden University, of which it forms the medical faculty. It is located in Leiden, Netherlands. LUMC is a modern university medical center for research, education and patient care. Its research practice ranges from pure fundamental medical research to applied clinical research.

Fuzhou Maixin Biotech Co., Ltd. (doing business as MXB Biotechnologies), part of Beijing Strong Biotechnologies, Inc., is a Chinese company located in Fuzhou. The firm engages in production, research & development and sales and focus on tissue-based diagnostics specifically IHC antibodies, reagents and the automation of IHC and ISH. It was founded in 1993. Xiao Ya Wang is the current CEO of the firm. Fuzhou Maixin Biotech Co. Ltd. acquired Fuzhou Maixin Biotech Co., Ltd. on September 30, 2020 for $255.21 million.

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Zhejiang Fengneng Pharmaceutical Technology Co., Ltd., established on 2020-09-24, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Internet Information Service for Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Chemical product sales(No licensed chemical products);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.